Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice.

ABSTRACT: P60, a Foxp3 inhibitory peptide, can hinder the regulatory T cell (Treg) activity and impair tumor proliferation. However, low systemic stability and poor specificity have led to daily dosing to achieve therapeutic effect. Therefore, this study aims to improve P60 stability and specific delivery through its encapsulation in liposomes targeting CD25, constitutively expressed in Tregs. P60 liposomes formulated with DSPE-PEG₇₅₀ or DSPE-PEG₂₀₀₀ were incubated with DSPE-PEG₂₀₀₀-Maleimide micelles conjugated to Fab' fragments of anti-CD25 to develop two targeted formulations or immunoliposomes (IL): IL-P60₂₀₀₀ (DSPE-PEG₂₀₀₀ only) and IL-P60₇₅₀ (combining DSPE-PEG₇₅₀ and DSPE-PEG₂₀₀₀). P60 encapsulation effici

SUBMITTER: Serrano A 

PROVIDER: S-EPMC11695603 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature